| 04/17/20 | AZN.L, AZN | Trastuzumab deruxtecan (BLA) | FDA decision on Trastuzumab deruxtecan or treatment of patients with HER2-positive metastatic breast cancer |
| 04/04/20 | LLY | Empagliflozin/Iinagliptin/Metformin Triple Combination Tablet (NDA) | FDA decision on the triple combination tablet for adults with Type 2 Diabetes |
| 04/04/20 | BMY | Luspatercept (BLA) | FDA decision on Luspatercept for adult patients with very low- to intermediate-risk MDS-associated anemia |
| 04/04/20 | XLRN | Luspatercept (BLA) | FDA decision on Luspatercept for adult patients with very low- to intermediate-risk MDS-associated anemia |
| 03/28/20 | RMTI | IV Triferic (NDA) | FDA decision on IV Triferic for iron deficiency in chronic kidney disease patients receiving hemodialysis |
| 03/26/20 | HRTX | HTX-011 (Resubmitted NDA) | FDA decision on HTX-011 for the management of postoperative pain |